How AIM ImmunoTech Inc. is positioning Ampligen to overcome checkpoint inhibitor resistance in ovarian cancer
Can AIM ImmunoTech Inc.’s Ampligen improve checkpoint inhibitor responses in ovarian cancer? Explore the Phase 2 findings and implications.
Does Verastem Oncology’s updated RAMP 201 dataset change the outlook for low-grade serous ovarian cancer treatment?
Verastem Oncology’s two-year ovarian cancer data strengthen the case for avutometinib plus defactinib. Read what this means next.